1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

  • August 2016
  • 79 pages
  • GlobalData
Report ID: 1957646

Summary

Table of Contents

Search Inside

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

Summary
Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world.
ACS is an umbrella term that describes conditions in which blood flow to the heart is blocked or reduced due to atherosclerotic plaques composed of white blood cells, cholesterol, and fat. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person’s symptoms, changes in the ST tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death.

Epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 Million cases in 2015 to 30.62 Million cases in 2025, at an Annual Growth Rate (AGR) of 2.03%. Throughout the forecast period, the diagnosed prevalent cases of ACS in the US will constitute the highest proportion in the 7MM at approximately 54%.
In the 7MM, the diagnosed prevalent cases of ACS will be higher in men (61.81%) and in the age group older than 65 years (62.84%). STEMI, NSTEMI, and UA will constitute approximately 25%, 40%, and 35% of the diagnosed prevalent cases of ACS in the 7MM.

In the 7MM, epidemiologists project ACS hospitalizations to increase from 1.63 Million cases in 2015 to 1.71 Million cases in 2025 at an AGR of 0.51%. The US constitutes around 40% of the total hospitalized ACS cases in the 7MM for the year 2015 and will be the market with the highest number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (62.85%) and in the age group older than 65 years (69.34%).

The report “EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025” provides an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015–2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).

Scope
- The Acute coronary syndrome (ACS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015-2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).
- The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy
The ACS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global ACS market.
- Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ACS therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Minimally invasive mitral valve repair and replacement procedures. Combined report. European reimbursement report

  • $ 19250
  • Industry report
  • April 2017
  • by Med Tech Reimbursement Consulting

Report presents summary of the reimbursement situation in Europe for all developed or currently under development minimally invasive (transapical approach via mini-thoracotomy) and transcatheter mitral ...

Robotic surgery interventions. European reimbursement report

  • $ 10450
  • Industry report
  • May 2017
  • by Med Tech Reimbursement Consulting

Report presents summary of reimbursement situation for procedures using robotic equipment in European countries. Five the most common robotic surgical procedures are included into report: total prostatectomy ...

Angioplasty of arteries of lower extremities for peripheral artery disease. European reimbursement report

  • $ 10450
  • Industry report
  • April 2017
  • by Med Tech Reimbursement Consulting

Report presents summary of the reimbursement situation in Europe for a group of angioplasty procedures of arteries of lower extremities for peripheral artery disease (plain and drug-eluting balloon angioplasty, ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.